Neratinib is a tyrosine kinase inhibitor anti-tumor drug also used in the treatment of breast cancer with results that have lasted up to date. In its simplest terms, Neratinib at https://www.aasraw.com/products/neratinib/ works by stopping the tyrosinase from completing its normal function of converting the messenger RNA for transcription into DNA.
The tyrosinase is responsible for making sure that the message you are just typing into your keyboard gets transcribed into the correct DNA sequence before being passed on to the next person for execution. As you may know, the human body cannot make its own copy of the DNA message, which is what makes transcription and sequencing of DNA messages possible at all.
This means that any abnormalities that may be present in the DNA message before it is passed on are actually pre-disposition events to the tumor that caused the cancer to occur.
Unfortunately, tumors can form in other areas other than the breast, such as the colon, ovaries, lungs, rectum, liver or any other place where DNA can get expressed. However, they still need to get passed to the lymphatic system before there is a chance of the malignant transformation. This is where theatinib and/or levorotorgicin come into play.
This is where the two anti-cancer drugs work in synergy and why it has been effective for women with non-Hodgkins lymphoma, particularly those who have had radiation therapy. The idea behind both drugs is that they stop the messenger RNA from performing its normal function and failing to transport the DNA message into the cells.
So in effect, neratinib delays the formation of the cancerous cells while at the same time exposing them to less damage so that they do not have to form at all. While both drugs are relatively new for use in the treatment of non-Hodgkins lymphoma, their success has been proven by patients who have used them with remarkable results. For this reason, the National Cancer Institute is currently funding clinical studies for both drugs.
In addition to these two medicines, a doctor may also prescribe tamoxifen for women with Stage IV breast cancer that have firm evidence of BPH (benign prostatic hyperplasia) or are unresponsive to treatments like hormone therapy or topical creams. While these medicines can help make the symptoms of the disease less intense, they cannot do anything to actually kill the cancer cells.
Doctors may also recommend the use of surgical removal of the ovaries as treatment for Stage IV non-Hodgkins lymphoma, in which case the doctor would not recommend tamoxifen. As always, your health care professional will want to hear from you regarding any effects you may experience, including skin rash, hair loss, or abnormal bleeding.
At the very least, these two medicines should be added to your patient’s prescription list as additional treatment options. You should also discuss the effects and benefits with your doctor to ensure that you get the most effective treatment possible.
Remember that while Neratinib like Erlotinib is relatively new, many patients have gotten relief from its use through other medicines. There is no conclusive evidence that these other medicines are better than Neratinib. That said, your doctor may have information that can lead you to consider one medicine over another.